GI Innovation singed MoU with CellKey for joint biomarker research

GI Innovation, a new innovative drug development company, announced on February 23 that it has signed a biomarker joint research MoU with CellKey, a Glycoprotein biomarker development company, to develop next-generation innovative immuno-oncology.

The MoU ceremony was held in GI Innovation’s head office and Myoung-Ho Jang Chairman, Na-Ri Yun VP, Ji-Soo Kim director of GI Innovation and Nam-Yong Lee CEO, Kwang-Hoe Kim Head of Bio-R&D center, Sang-Yong Lee COO of CellKey have attended.

Through this MoU, GI Innovation will progress joint biomarker research for developing of next generation protein and antibody drugs using GI Innovation’s bispecific fusion protein development platform GI-SMARTTM and AI-powered biomarker discovery platform SpAC9 Pipeline. In addition, both companies will progress jointly published thesis, academic publication, research business, and etc.

Biomarker is a biological index that can sense symptoms of in the body using protein, DNA, RNA, metabolite, and etc. The more construct the multiple panels are the more possibility to raise accuracy and diagnose of early cancer.

In particular, AI and cloud-powered SpAC9 Pipeline of CellKey enables discovery of the most optimal multi-biomarker panels, consisting of glycoproteins and proteins, up to 100 times faster than with conventional analysis methods.

With this strategic partnership, both companies will expect that GI Innovation will predict drug responses on GI Innovation’s immuno-oncology and reinforce reliability and efficacy of treatment through the biomarker discovery that can monitor on treatment effects and CellKey expects to improve upon effects of personalized treatments and cancer diagnostic biomarker business.
MB Bureau